Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. - Wikidata - wikimedia - TriplyDB

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

http://www.wikidata.org/entity/Q42556370

about

Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas Hepatic late adverse effects after antineoplastic treatment for childhood cancer Cardioprotective interventions for cancer patients receiving anthracyclines Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Cardioprotective interventions for cancer patients receiving anthracyclines Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Cardiac toxicity in cancer survivors Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model Effect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male rats Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Cardiotoxicity of cancer therapy.A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.Cardiovascular disease in adult survivors of childhood cancer.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.Chemotherapy in Ewing's sarcoma.Dexrazoxane for the treatment of chemotherapy-related side effects.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients Chemotherapy-induced cardiotoxicity.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Dexrazoxane as a cardioprotectant in children receiving anthracyclines Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Anthracycline cardiotoxicity.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Anthracycline cardiotoxicity in childhood.Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database The role of antioxidants in the era of cardio‑oncology.Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

P2860

Q24234049-12DE09DE-46C0-4C56-ADDC-E58EA2A86C8D Q24235525-FB62467C-EEEC-4513-8FA5-4E0424586394 Q24236338-862A2852-4B7F-4722-8344-2E0DAFC7EDE5 Q24240568-0B02C4CD-C03F-4A5B-98DC-F4C0B4FAC004 Q24243021-3EEA63DB-847C-4742-940F-2BF2ADA9CA0E Q24628695-30F323AD-D965-4913-BAE0-CA38649AE6FA Q26851957-E4304A93-9A7C-446F-BFFD-3201EB420026 Q33404672-FF3A8575-7656-4F80-A9C1-87B9ABAC052F Q33455575-4E787A2F-C703-4956-9115-EFB3ECACA523 Q33619867-92C38017-9F16-45E9-A03A-C6293A4F1799 Q33704056-2F51AE3E-FDC7-440D-A7DE-4DB1BAE26ECB Q33735167-2AA71429-1C38-407B-B204-0651A5687703 Q33812953-55D6C81B-C908-4F6C-9BB5-E5A73ECDB396 Q34042984-2805F033-1F0A-4084-9FF7-9DDFBE9B4594 Q34073681-9AF68B4D-DFDC-444C-84B0-31DD022474B7 Q34120033-5982B6B4-F547-4D58-9D11-EAB63D9B167F Q34164686-8EDF5185-B0CE-4CBA-BF53-5D2C6C554F45 Q34211957-C3440D6A-8AE8-4CE5-BE22-1D00EA04273B Q34253158-8445D733-C9E0-4C70-BEDE-2FADE7FDA0A5 Q34258080-92BED1B3-CA3F-4A48-ACA7-447D7EC327D5 Q35562745-414D07E8-FB15-4CDA-90D1-7E5E0770FEF6 Q35583768-9B2774AE-2E98-4379-BB27-5B3FF4F1F725 Q35849444-A3FFE3D3-A249-4DC0-8C4D-7EC3D859877B Q35947024-188A1E2C-0F5F-4965-A201-49C2AE75AEDD Q36053116-E20AE606-D47B-4AF8-BE29-E90B63FC2564 Q36097717-71AF272F-BE5A-4AA0-A784-C552680B2473 Q36099606-D13813E8-DC99-4856-A02B-F84311698492 Q36184665-D147FF42-597F-4BA5-B73F-FB924BC254EE Q36568908-D0660DCA-3FB0-4871-A8A4-E631D25594E0 Q36624983-78E9CDC7-44A2-4358-8440-CA6C4C562399 Q36643541-1DE874E8-2872-4BF5-8643-9053FB94CF60 Q36653789-7BB7E62D-946D-4268-AEB6-661477CE89BF Q36828128-221190A8-9DAE-4E1D-BDAE-54F6358C4A7E Q37165394-A13F5EBD-52BB-4636-976D-934CE1BD4066 Q37455829-3D098635-0DC0-4256-AC9D-DABC30FB39C3 Q37569911-F04F0131-779C-468D-8F32-202067EDD9BE Q37626273-42AAA9D8-C519-49C9-B848-20B64940E5F9 Q38264693-0B9C67A3-C065-43F2-A0C1-2B1881ADD0F1 Q38838517-31416DC2-BB09-47DE-AE1F-12EF056C9EC8 Q39229404-BA0E0F26-A819-4129-B257-A298BD45128D

P2860

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

http://www.wikidata.org/entity/Q42556370

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Randomized trial of the cardio ...... ents treated with doxorubicin.

@en

Randomized trial of the cardio ...... ents treated with doxorubicin.

@nl

type

label

Randomized trial of the cardio ...... ents treated with doxorubicin.

@en

Randomized trial of the cardio ...... ents treated with doxorubicin.

@nl

prefLabel

Randomized trial of the cardio ...... ents treated with doxorubicin.

@en

Randomized trial of the cardio ...... ents treated with doxorubicin.

@nl

P1433

Q42556370-5B93EC62-CE95-42F7-8C0D-B025B7F42E61

P1476

Q42556370-83373C65-2B3A-455E-89B1-A27CDF312802

P2093

Q42556370-055747D3-A058-4E34-B121-9B32DEA348F0

Q42556370-39671348-B9ED-434A-82B4-B755D6010345

Q42556370-8856FF1A-9685-4DEC-BFBD-52F730F0183C

Q42556370-8FC08BFD-3DF3-4C0D-8130-C3565D17DC82

Q42556370-910E1C1C-789A-453F-9F71-4D3E6D8F8902

Q42556370-B17AB838-AD93-4109-9CD5-F8DEA586EC06

Q42556370-C264D2EF-4A92-489C-94F8-6A1C2414A38F

Q42556370-D1D1C149-52DA-4589-94E5-E435A3900BCE

Q42556370-D64C587C-8170-4199-BA7C-A675CB6D5487

Q42556370-E945465F-4E58-4A89-873C-A9FA6473DBE1

P304

Q42556370-C6906BE5-D364-40F3-8381-490FA260D207

P31

Q42556370-32FE61A3-CC7A-4381-8983-114F706C30F2

P356

Q42556370-91A047A0-08F0-4151-B5F2-5140F4A45882

P407

Q42556370-8951BDB3-D8A2-4F9E-910E-B71A32E3C9AC

P433

Q42556370-25BF32C6-4823-45C4-B67D-8BC977021FEF

P478

Q42556370-917C0B70-4553-4FF4-9DAF-574130384888

P577

Q42556370-0D4A2329-F95E-49AA-BA39-DC7B95E3347D

P698

Q42556370-976476A8-73FE-45F7-882A-C55FF874CA95

P921

Q42556370-A57F71F9-3378-4094-AFA2-CC9B20A8A42E

P356

JCO.1996.14.2.362

P1433

Journal of Clinical Oncology

P1476

Randomized trial of the cardio ...... ents treated with doxorubicin.

@en

P2093

C C Chen

http://www.w3.org/2001/XMLSchema#string

D G Poplack

http://www.w3.org/2001/XMLSchema#string

D Venzon

http://www.w3.org/2001/XMLSchema#string

F M Balis

http://www.w3.org/2001/XMLSchema#string

L H Wexler

http://www.w3.org/2001/XMLSchema#string

L Weaver-McClure

http://www.w3.org/2001/XMLSchema#string

M E Horowitz

http://www.w3.org/2001/XMLSchema#string

M P Andrich

http://www.w3.org/2001/XMLSchema#string

N Avila

http://www.w3.org/2001/XMLSchema#string

P Jarosinski

http://www.w3.org/2001/XMLSchema#string

P304

362-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1996.14.2.362

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

1996-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8636745

http://www.w3.org/2001/XMLSchema#string

P921